Moderna’s combined Covid-19 and flu vaccine matched the efficacy of single shots in late-stage trial results published on Monday, opening the door for the mRNA vaccine maker to seek approval for its third product.

In a phase 3 trial studying antibody responses in more than 8,000 adults aged 50 and over, Moderna said its combination vaccine proved as effective as its Covid shot administered separately alongside two popular seasonal flu jabs, Fluzone and Fluarix, which were given selectively to different age groups.

The combined shot also showed higher efficacy when targeting three specific seasonal flu strains, including H1N1 swine flu. Moderna plans to publish the interim data in a peer-reviewed journal and then submit it for US regulatory approval later this year.